Truist has increased its price target for Madrigal Pharmaceuticals to $743 from $709, while reiterating a Buy rating. This adjustment follows the company's Q3 2026 financial report, indicating a positive analyst sentiment post-earnings.
Truist, a prominent financial institution, has raised its price target for Madrigal Pharmaceuticals (MDGL) to $743, up from $709, and maintained its 'Buy' rating. This positive revision comes after Madrigal's third-quarter 2026 financial reporting, suggesting that the results were well-received by the analyst. For traders, this indicates continued bullish sentiment from a major firm, potentially leading to short-term positive momentum for MDGL shares. The long-term implication is a reinforced positive outlook on the company's future performance, assuming the Q3 results support this increased valuation. A key opportunity for traders lies in potential upward movement driven by increased investor confidence following this analyst upgrade.